Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Dupixent achieved a 20% year-over-year increase in global net sales, driven by strong demand across all approved indications.
- EYLEA HD sales grew by 54% year-over-year, maintaining its position as a leader in the anti-VEGF category.
- Regeneron Pharmaceuticals Inc (REGN) has a robust pipeline with approximately 45 product candidates in clinical development, including four regulatory approvals and nine regulatory submissions in 2025.
- Libtayo's US sales increased by 21% year-over-year, establishing it as a cornerstone therapy for advanced non-melanoma skin cancer.
- The company is making significant investments in R&D and manufacturing, with over $7 billion planned for US expansions to support growth and innovation.
- EYLEA US net sales declined by 39% compared to the first quarter of the previous year, impacted by increased competition and lower wholesaler inventory levels.
- The FDA issued a complete response letter for the EYLEA HD prefilled syringe, delaying its approval and impacting potential sales growth.
- Regeneron Pharmaceuticals Inc (REGN) faces challenges from increased use of low-cost off-label Avastin due to patient affordability issues.
- The company has experienced multiple complete response letters (CRLs) and regulatory delays, raising concerns about its regulatory performance.
- There is uncertainty regarding the reopening of foundation funding for patient assistance, which affects the affordability of EYLEA for some patients.
Welcome to the Regeneron Pharmaceuticals first-quarter 2025 earnings conference call.
My name is Josh, and I will be your operator for today's call.
(Operator Instructions)
Please note that this conference call is being recorded.
I will now turn the call over to Ryan Crowe, Senior Vice President, Investor relations. You may begin.
Thank you, Josh.
Good morning, good afternoon, and good evening to everyone listening around the world.
Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call.
An archive and transcript of this call will be available on Regeneron's Investor Relations website shortly after the call ends.
Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President, and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President and Chief Scientific Officer; Marion McCourt,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
